ClinicalTrials.gg
CompletedNCT05404334Updated Aug 13, 2024

of Androgen Receptor Expression in Breast Cancer With or Without BRCA Mutation

An observational study in Breast Cancer, sponsored by Banaras Hindu University. Completed at 1 site in India. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by Banaras Hindu University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
231
Ages
18 Years to 99 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 182 studies in Breast Neoplasms with a site in India — 20 open to participants now, 53 under way, 37 of them phase 3. Breast Neoplasms · India.

Enrollment
13th of 19
231 · median 595
Started
2021
with 15 others
Observational
19 of 182
2 open now
Registered
147th of 182
by date

Among the 182 studies in Breast Neoplasms with a site in India, this one is the 13th largest by enrollment of the 19 observational ones that give a count, is one of 16 that started in 2021, is one of 19 observational ones, and was the 147th registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

20 of the 182 studies in Breast Neoplasms with a site in India are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 99 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Breast Neoplasms with a site in India, or all of them as a file.
02

Study summary

Androgen Receptor is extensively expressed in BRCA and its role in the disease may differ depending upon molecular subtypes and stages. Androgen Receptor (AR) may act as an antagonist of estrogen receptor α (ERα), in ERα induced effect, whereas in the absence of estrogens, AR may act as an agonist, of ERα- promoting tumor. Thus, depending on the BRCA micro-environment, both agonists and antagonists of the AR have been suggested for therapeutic approaches.

Read the detailed description

The rate of AR positivity in breast cancer is about 60% to 80%. Biologically the AR pathway has cross talk with several other key signaling pathway, including the PI3K/Akt/mTOR and MAPK Pathways, and with other receptor, including estrogen receptor and human epidermal growth factor receptor-2. In clinical trials in patients with breast cancer, AR targeted therapies such as AR agonists, AR antagonists, PARP inhibitors, and PI3K inhibitors have shown promising results. The use of AR targeted therapies in conjunction with other agent has been investigated for overcoming resistance to AR focused treatments. Thus, the value of AR positivity as a prognostic marker has not been identified. Several retrospective clinical studies have shown that AR might be a prognostic or predictive factor in breast cancer. BRCA1 mutation accounts for the progress of hereditary breast cancers and is in connection with unique clinicopathological characteristics compared with sporadic breast cancers. The database is still evolving and newer mutation and their significance is being found every day. Also, there were several limitations to these previous studies. First, the cut-off for AR positivity was arbitrary. In most of the studies, the cut-off points were 1% or 10% and weren't enough to predict carcinoma survival. Moreover, quite 90% of the studies were conducted in non-Asian regions. Most of the studies involving Asian patients studied the prognostic role of AR in TNBC patients, with inconclusive results. There are only a few studies from Indian continents and none has correlated the AR expression with BRCA.

After the written inform consent in case of fresh recruitment the blood will be collected and tissue blocks will be obtained, use of already available blocks of patients who earlier participated in another study is also proposed.

(a) Samples will be stored for DNA study and will be frozen in liquid nitrogen and stored at -80 °C until further processing.

(samples will store in 10% formalin at room temperature (RT) for Immunohistochemistry

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Patients with breast cancer and benign breast diseases

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histology proven cases of breast cancer

Exclusion criteria

Exclusion Criteria:

  • Patients with prior treatment
  • Pregnant and lactating women
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
231 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Breast Cancer

    Patients with histologically proven breast cancer

    Diagnostic Test: Androgen receptor status and BRCA mutation

  • Benign breast disease

    Patients with benign breast diseases undergoing surgical resection

    Diagnostic Test: Androgen receptor status and BRCA mutation

Interventions

  • Diagnostic testAndrogen receptor status and BRCA mutation

    Androgen receptor status by IHC and germ line BRCA mutation

06

What researchers measure

Primary outcomes

  1. Receptor expression

    Androgen receptor expression and its correlation with molecular subtypes of breast cancer

    Time frame: 6 months

  2. BRCA1 and BRCA2 mutations

    BRCA mutations and its correlation with molecular subtypes of breast cancer

    Time frame: 6 months

Secondary outcomes

  1. AR and BRCA

    Correlation of Androgen receptor expression with BRCA mutation

    Time frame: 6 months

07

Study locations

1 site
  • Banaras Hindu University
    Varanasi, UP 221005, India
08

References and documents

Publications

  • Anand A, Singh KR, Kumar S, Husain N, Kushwaha JK, Sonkar AA. Androgen Receptor Expression in an Indian Breast Cancer Cohort with Relation to Molecular Subtypes and Response to Neoadjuvant Chemotherapy - a Prospective Clinical Study. Breast Care (Basel). 2017 Jul;12(3):160-164. doi: 10.1159/000458433. Epub 2017 Jun 16. PubMed 28785183 ↗
  • Vidula N, Yau C, Wolf D, Rugo HS. Androgen receptor gene expression in primary breast cancer. NPJ Breast Cancer. 2019 Dec 10;5:47. doi: 10.1038/s41523-019-0142-6. eCollection 2019. PubMed 31840050 ↗
  • Zhang L, Fang C, Xu X, Li A, Cai Q, Long X. Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis. Biomed Res Int. 2015;2015:357485. doi: 10.1155/2015/357485. Epub 2015 Jan 28. PubMed 25695063 ↗

Individual participant data

Plan to share: Yes — On request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 3 months

Access criteria: on request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jul 2024, 36 months.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 36 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2022
First posted
Jun 3, 2022
StartActual
Jul 1, 2021
Primary completionActual
Jul 1, 2024
CompletionActual
Jul 1, 2024
Last update
Aug 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05404334
Lead sponsor
Banaras Hindu University
Responsible party
Manoj Pandey (Professor, Banaras Hindu University) — Principal investigator
First posted
Jun 3, 2022
Start date
Jul 1, 2021
Primary completion
Jul 1, 2024
Completion
Jul 1, 2024
Last update
Aug 13, 2024

Study contacts

Manoj Pandey, MS, PhD
principal investigator · Banaras Hindu University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion